Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017

BOSTON, Oct. 26, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on November 2, 2017, to discuss the financial results for the third quarter ended September 30, 2017, as follows:

Audio webcast (live & archive): www.juniperpharma.com, under 'Investors' or click here.

The teleconference replay will be available approximately one hour after completion through Thursday, November 9, 2017, at 1-877-344-7529 (U.S.), 1-855-669-9658 (Canada) or 1-412-317-0088 (International). The replay access code is 10113476.

The archived webcast will be available for one year via the aforementioned URLs.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. The Company is also leveraging its differentiated intravaginal ring technology, which offers the potential to address unmet needs in women's health. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

Crinone^® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Investor Contact:  

Laura Perry or Heather Savelle

Argot Partners 

212-600-1902

laura@argotpartners.com

heather@argotpartners.com

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.  

Follow us on LinkedIn  

View original content with multimedia:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-report-third-quarter-2017-results-on-november-2-2017-300544619.html

SOURCE Juniper Pharmaceuticals, Inc.